Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul;63(7):721-35.
doi: 10.1007/s00262-014-1549-4. Epub 2014 Apr 8.

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

George C Prendergast  1 , Courtney Smith, Sunil Thomas, Laura Mandik-Nayak, Lisa Laury-Kleintop, Richard Metz, Alexander J Muller
Affiliations
Review

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

George C Prendergast et al. Cancer Immunol Immunother. 2014 Jul.

Abstract

Genetic and pharmacological studies of indoleamine 2,3-dioxygenase (IDO) have established this tryptophan catabolic enzyme as a central driver of malignant development and progression. IDO acts in tumor, stromal and immune cells to support pathogenic inflammatory processes that engender immune tolerance to tumor antigens. The multifaceted effects of IDO activation in cancer include the suppression of T and NK cells, the generation and activation of T regulatory cells and myeloid-derived suppressor cells, and the promotion of tumor angiogenesis. Mechanistic investigations have defined the aryl hydrocarbon receptor, the master metabolic regulator mTORC1 and the stress kinase Gcn2 as key effector signaling elements for IDO, which also exerts a non-catalytic role in TGF-β signaling. Small-molecule inhibitors of IDO exhibit anticancer activity and cooperate with immunotherapy, radiotherapy or chemotherapy to trigger rapid regression of aggressive tumors otherwise resistant to treatment. Notably, the dramatic antitumor activity of certain targeted therapeutics such as imatinib (Gleevec) in gastrointestinal stromal tumors has been traced in part to IDO downregulation. Further, antitumor responses to immune checkpoint inhibitors can be heightened safely by a clinical lead inhibitor of the IDO pathway that relieves IDO-mediated suppression of mTORC1 in T cells. In this personal perspective on IDO as a nodal mediator of pathogenic inflammation and immune escape in cancer, we provide a conceptual foundation for the clinical development of IDO inhibitors as a novel class of immunomodulators with broad application in the treatment of advanced human cancer.

PubMed Disclaimer

Conflict of interest statement

G.C. Prendergast, R. Metz and A.J. Muller state a conflict of interest as shareholders and G.C. Prendergast also a grant recipient and a member of the scientific advisory board for New Link Genetics Corporation, a biopharmaceutical company that has licensed IDO intellectual property for clinical development from the Lankenau Institute of Medical Research, as described in U.S. Patents Nos. 7705022, 7714139, 8008281, 8058416, 8383613, 8389568, 8436151, 8476454 and 8586636. The other authors state no conflict of interest.

Figures

Fig. 1
Fig. 1
Sites of IDO expression and action in cancer. IDO expression has been documented in a variety of cells in tumors and tumor-draining lymph nodes (and other metastatic sites) including malignant cells as well as other stromal, vascular and immune cells indicated. Both tryptophan deprivation and kynurenine production mediated by IDO has been implicated in inflammatory processes and the generation of antigenic immune tolerance (immune escape). The figure summarizes the general effects that have been described on T cell function at each site. APC antigen-presenting cell (e.g., dendritic cell), MDSC myeloid-derived suppressor cell, TAM tumor-associated macrophage, TAN tumor-associated neutrophil, Teff T effector cell, Treg T regulatory cell
Fig. 2
Fig. 2
IDO programs a pathogenic inflammatory state that supports multiple traits of cancer progression. IDO is highlighted in traits where its role has been functionally implicated in preclinical and clinical studies. The panel below shows the outcome of a regimen of inflammatory skin carcinogenesis in wild-type (WT) and IDO1-deficient (KO) mice, illustrating the essential contributions of IDO function [40]
Fig. 3
Fig. 3
IDO regulatory and effector signaling pathways. Multiple upstream-acting regulatory pathways include cell surface receptors which act through intermediary transcription factors (light blue boxes) to stimulate IDO transcription. IDO is also controlled at the level of protein stability by SOCS3 (not shown). Three downstream-acting effector pathways mediate effects of IDO activity (tan boxes), leading to stimulation of AhR by kynurenine binding along with mTOR and eIF-2 suppression due to tryptophan deprivation. Key mediators in each pathway are shown, including IDO2 elevation (via AhR), S6 kinase suppression (via mTOR suppression), and IL-6 and CCL2 elevation (via eiF-2 modulation)
Fig. 4
Fig. 4
Strategies for blocking IDO function in cancer. Attenuation of the tumor suppressor Bin1 in malignant cells relieves suppression of IDO transcription through effects on Jak/STAT and NF-kB dependent pathways. IDO upregulation by this mechanism or the stimulatory mechanisms presented in Fig. 3 manifests IDO as a target for cancer therapy, through expression blockade, enzymatic inhibition or effector signal blockade
Fig. 5
Fig. 5
Tryptophan deprivation by IDO generates signals sensed by distinct amino acid sufficiency and deficiency pathways. Trp deficiency is sensed by the integrated stress kinase GCN2 that inhibits eIF-2α and alters translation. Through a distinct pathway, the lack of Trp sufficiency causes mTOR to be inactivated, leading to autophagy via LC3 de-repression and translational blockade via S6 kinase inactivation. D-1MT acts as a peculiar mimetic of Trp in the sufficiency pathway, thereby functionally reversing the effects of IDO on mTOR. The figure is modified from Metz et al. [74]
Fig. 6
Fig. 6
Immunochemotherapy of the future with IDO inhibitors. Multiple applications are suggested in various combination with tolerance blockade (immune checkpoint inhibitors), active immunotherapeutic interventions (vaccines or CART [chimeric antigen receptor T cells]), and classical/targeted chemotherapy or radiotherapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Prendergast GC, Jaffee EM. Cancer immunologists and cancer biologists: why we didn’t talk then but need to now. Cancer Res. 2007;67(8):3500–3504. - PubMed
    1. Prendergast GC. Immunological thought in the mainstream of cancer research: past divorce, recent remarriage and elective affinities of the future. Oncoimmunology. 2012;1(6):793–797. - PMC - PubMed
    1. Prendergast GC, Jaffee EM, editors. Cancer immunotherapy: immune suppression and tumor growth. 2. New York: Academic Press; 2013.
    1. Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res. 2005;65(18):8065–8068. - PubMed
    1. Muller AJ, DuHadaway JB, Sutanto-Ward E, Donover PS, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunomodulatory target of the tumor suppressor gene Bin1, potentiates cancer chemotherapy. Nature Med. 2005;11:312–319. - PubMed

Publication types

Substances